Added to YB: 2026-03-23
Pitch date: 2026-03-18
DRTS [neutral]
Alpha Tau Medical Ltd.
Author Info
No bio for this author
Company Info
Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer.
Market Cap
$644.2M
Pitch Price
N/A
Price Target
N/A
Dividend
N/A
EV/EBITDA
-14.71
P/E
-13.84
EV/Sales
N/A
Sector
Health Care Equipment and Supplies
Category
growth
DRTS (Alpha Tau Medical) - The Only Implantable Alpha Emitter Therapy in the World With Regulatory Approval
DRTS (overview): Only implantable alpha emitter therapy w/ regulatory approval globally. Japan approval Feb 2026 for head/neck cancer; FDA Breakthrough Device designation + 5 US IDE trials (skin, oral, breast, pancreatic, liver). $76.9M cash, 7.45x current ratio, no dilution risk. $657M mkt cap in hottest M&A vertical (BMS paid $4.1B for RayzeBio, Novartis $1B for preclinical Mariana). Citi $9 PT, HC Wainwright $12 PT. Risks: US trial delays, execution, Piper $5 PT downgrade.
Read full article (4 min)